Literature DB >> 22153529

Should a radiological diagnosis of hepatocellular carcinoma be routinely confirmed by a biopsy? No.

Douglas M Heuman1, HoChong S Gilles, Cynthia Solomon, Jasmohan S Bajaj.   

Abstract

Modern multiphase diagnostic imaging allows diagnosis of hepatocellular carcinoma with high specificity in a large proportion of cases. Additional aspects of tumor biology also can be evaluated noninvasively through observation of tumor behavior (growth rate, satellites, vascular invasion) and other indicators of tumor biology (avid uptake of fluorodeoxyglucose, high circulating levels of tumor markers such as alphafetoprotein). Routinely requiring biopsy confirmation for diagnosis of HCC exposes many patients to unnecessary risk, may delay diagnosis, and in some cases leads to withholding of potentially beneficial treatment. Biopsy for assessment of tumor molecular markers is promising but remains investigational. When diagnosis of HCC is clinically evident by imaging criteria, tumor biopsy should not be required prior to initiating treatment. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 22153529     DOI: 10.1016/j.ejim.2011.09.014

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  2 in total

1.  Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).

Authors:  Ying Ding; Sheng-Xiang Rao; Wen-Tao Wang; Cai-Zhong Chen; Ren-Chen Li; Mengsu Zeng
Journal:  Cancer Imaging       Date:  2018-12-07       Impact factor: 3.909

Review 2.  Contemporary role of liver biopsy in hepatocellular carcinoma.

Authors:  Zeno Sparchez; Tudor Mocan
Journal:  World J Hepatol       Date:  2018-07-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.